There is no longer room for significant bargaining in centralized procurement, or even a small price increase. For example, this time insulin centralized procurement, the bidding prices for the renewal of the six products declared by Gan & Lee Pharmaceutical this time are all higher than the medium price at the end of 2021.
Gan & Lee Pharmaceutical Co., Ltd. declared a total of six products this time, namely sperm protein human insulin mixed injection (30R), insulin aspart injection, and insulin aspart injection 30 injection, all of which were quoted at 25.9 yuan/piece, insulin lispro injection and protein human insulin mixed injection (25R) were quoted at 35.55 yuan/piece, and insulin glargine injection was quoted at 65.3 yuan/piece.
Third-generation insulin: Eli Lilly is basically Class C, which has been divided into a lot of volumes, becoming the biggest loser in this round of centralized procurement. However, Eli Lilly's insulin product line accounts for a small proportion and ignores the overall revenue, and the GLP-1 series products are selling well, which will not affect the overall profit. Sanofi insulin glargine is class A, and the price reduction is not much, basically preserving the market. Novo Nordedete insulin injection quoted a price of 82.2 yuan/piece, which became a scrapped standard.
The most concerned thing about this collection is the shortlisting of Novo Nordisk insulin aspart, which is the largest variety. Judging from the results, Mendong and Mendong 30 all entered Group B, which belonged to the second situation, and Class C entered Class B, with a transfer volume of 15%, 55 million * 0.15 = 8.25 million, which was divided by other Class A manufacturers, which was already the best result for Novo Nordisk.
